ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,214.50
-0.10%
S&P ASX All Technology
3,562.20
0.19%
Brent Oil
78.695
0.00%
US Dollar vs AUD
1.48126
0.00%
Bitcoin
62,698.96
0.40%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Akebia Therapeutics Inc (AKBA) Share Price

Akebia Therapeutics Inc

Akebia Therapeutics Inc (AKBA)

NASDAQ
1.32
0.04
(3.13%)
Closed 12 October 7:00AM
Delayed by 15 minutes
1.32
0.00
(0.00%)
After Hours: 10:59AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.32
Bid
1.29
Offer
1.33
Volume
1,320,479
1.27 Day's Range 1.32
0.7801 52 Week Range 2.48
Market Cap
277.58M
Previous Close
1.28
Open
1.28
Last Trade
100
@
1.32
(formt)
Last Trade Time
Financial Volume
US$ 1,706,659
VWAP
1.2925
Average Volume (3m)
1,623,309
Shares Outstanding
210,288,210
Dividend Yield
-
PE Ratio
-5.31
Earnings Per Share (EPS)
-0.25
Revenue
194.62M
Net Profit
-51.93M

About Akebia Therapeutics Inc

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.akebia.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Akebia Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AKBA. The last closing price for Akebia Therapeutics was US$1.28. Over the last year, Akebia Therapeutics shares have traded in a share price range of US$ 0.7801 to US$ 2.48.

Akebia Therapeutics currently has 210,288,210 shares in issue. The market capitalisation of Akebia Therapeutics is US$269.17 million. Akebia Therapeutics has a price to earnings ratio (PE ratio) of -5.31.

Ask ADVFN Intelligence (AI)

AKBA Latest News

More News

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 PR Newswire CAMBRIDGE, Mass., Oct. 10, 2024 Designed to help dialysis organizations incorporate new treatments...

10 October 2024
PR Newswire (US)

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis PR Newswire CAMBRIDGE, Mass., Oct. 7, 2024 U.S. Renal...

07 October 2024
PR Newswire (US)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Oct. 1, 2024 CAMBRIDGE, Mass., Oct. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®...

02 October 2024
PR Newswire (US)

Form EFFECT - Notice of Effectiveness

13 September 2024
Edgar (US Regulatory)

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis PR Newswire CAMBRIDGE, Mass., Sept. 5, 2024 Outcomes study will assess mortality...

05 September 2024
PR Newswire (US)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Sept. 3, 2024 CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- Akebia...

04 September 2024
PR Newswire (US)

Form S-3 - Registration statement under Securities Act of 1933

04 September 2024
Edgar (US Regulatory)

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics to Present at Upcoming Investor Conferences PR Newswire CAMBRIDGE, Mass., Aug. 26, 2024 CAMBRIDGE, Mass., Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq:...

26 August 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 August 2024
Edgar (US Regulatory)

Form 8-K - Current report

08 August 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0201-1.499888068051.34011.371.2558567021.3070786CS
4-0.13-8.965517241381.451.4851.2412369401.33912447CS
12-0.025-1.858736059481.3451.581.0716233091.37456338CS
26-0.23-14.83870967741.551.580.824962981.2290643CS
520.2624.52830188681.062.480.780127796321.412392CS
156-1.51-53.35689045942.833.350.24136641321.06501815CS
260-2.87-68.49642004774.1913.780.24136276002.29416001CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAMPCAMP4 Therapeutics Corporation
 10.75
(2,587.50%)
378.47k
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.23M
NIVFNewGenIvf Group Ltd
US$ 0.98
(63.42%)
58.51M
ATIFATIF Holdings Ltd
US$ 1.235
(58.33%)
3.85M
VERBVerb Technology Company Inc
US$ 7.91
(51.82%)
15.55M
BYUBAIYU Holdings Inc
US$ 0.299
(-35.28%)
11.11M
TURBTurbo Energy SA
US$ 2.1511
(-29.01%)
3.2M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
US$ 7.898
(-23.62%)
993.33k
VEEAVeea Inc
US$ 3.27
(-23.24%)
284.95k
INHDInno Holdings Inc
US$ 3.74
(-22.41%)
257.75k
JTAIJet AI Inc
US$ 0.1009
(23.50%)
340.09M
CDTConduit Pharmaceuticals Inc
US$ 0.116
(13.28%)
270.97M
NVDANVIDIA Corporation
US$ 134.80
(-0.01%)
170.27M
LUXHLuxUrban Hotels Inc
US$ 0.0532
(5.35%)
165.94M
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.23M

AKBA Discussion

View Posts
glenn1919 glenn1919 2 months ago
AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 months ago
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Krspecialized Krspecialized 3 months ago
I believe the current news releases may have answered your question. GLTA
👍️0
Toofuzzy Toofuzzy 4 months ago
Why do you say we have a gold mine here ?

Toofuzzy
👍️0
Krspecialized Krspecialized 4 months ago
There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!
👍️0
eyeownu eyeownu 5 months ago
SCARY MOVIE
👍️0
eyeownu eyeownu 5 months ago
https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast
👍️0
eyeownu eyeownu 5 months ago
added 2k@ 1.11
👍️ 1
glenn1919 glenn1919 5 months ago
AKBA................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 6 months ago
AKBA under $2

👍️0
eyeownu eyeownu 6 months ago
ask is stacked! someone needs to slap it.
👍️0
eyeownu eyeownu 6 months ago
$AKBA RELOAD
👍️0
Firestorm22 Firestorm22 6 months ago
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
Firestorm22 Firestorm22 6 months ago
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
ErnieBilco ErnieBilco 6 months ago
I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
👍️ 1
Firestorm22 Firestorm22 6 months ago
Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
👍️ 1
ErnieBilco ErnieBilco 6 months ago
Classic sell the news. Probable offering coming next week to dilute on the good news.
👍️0
Firestorm22 Firestorm22 6 months ago
Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
👍️0
Krspecialized Krspecialized 6 months ago
Long solid position here!
👍️0
Limey42 Limey42 6 months ago
Long term play. Congrats all!
👍️ 1
dugie100 dugie100 6 months ago
Something didn’t look good , I guess!
👍️0
TrendTrade2016 TrendTrade2016 7 months ago
AKBA should see 3 bucks
👍️0
TrendTrade2016 TrendTrade2016 7 months ago
AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
👍️0
glenn1919 glenn1919 7 months ago
AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 months ago
AKBA new 52 hi
👍️0
eyeownu eyeownu 7 months ago
$AKBA looking good damn! she fine.
👍️ 1
glenn1919 glenn1919 7 months ago
AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 7 months ago
$AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
👍️ 1
Monksdream Monksdream 7 months ago
AKBA 10Q March 4
👍️0
Tyrus603 Tyrus603 7 months ago
Excellent chart. Thank you for posting.

Found myself studying it for quite a bit.

As it really is a dream chart for both swing traders AND long term buy & hold investors alike.
👍️0
glenn1919 glenn1919 7 months ago
AKBA..............................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 8 months ago
$AKBA
👍️0
eyeownu eyeownu 8 months ago
$AKBA reversal incoming?
👍️0
eyeownu eyeownu 8 months ago
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

At the closing, Akebia drew the first tranche of $37.0 million and used the proceeds to pay down $35.0 million of principal outstanding from a loan agreement with Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit funds, plus interest and fees. The new agreement substantially extends the interest-only period in the event of vadadustat approval by the U.S. Food and Drug Administration (FDA) without requiring any principal repayment until December 31, 2025, with an option for Akebia to extend until December 31, 2026.
👍️0
eyeownu eyeownu 8 months ago
$AKBA profit taking! hope you took some off the table!
👍️0
eyeownu eyeownu 9 months ago
PDUFA explanation https://www.fool.com/terms/p/pdufa-date/

What percentage of PDUFA are approved?
Characteristic Percentage of drugs approved in 2023
Met PDUFA goal date* 89%
First cycle of review 84%
Approved in the United States before receiving approval in any other country 64%
Priority review 56%

From
👍️0
eyeownu eyeownu 9 months ago
$AKBA via stocktwit @Bidzill @fresh10 fresh - We have PDUFA date scheduled for March 27, 2024 concerning Vadadustat DD USA. Approval is de-risked and highly likely, IMO. We have product launch date first half of year for Vadadustat DD EU/Australia. We have phase 2 trial for AKB 9090 for second half of 2024. We have Auryxia all time/near all time high sales 2024. Good luck 🍀 to you and us.
👍️0
eyeownu eyeownu 9 months ago
https://www.tradingview.com/x/6Ykwijbc/
👍️0
eyeownu eyeownu 9 months ago
$AKBA from stocktwits

MORE GOOD NEWS - FDA Fast Track Designation is process designed to facilitate development & expedite drug review to treat serious conditions & fill UNMET MEDICAL NEED. Determining whether condition is serious enough for designation is matter of judgment … ARDS is life threatening & acute, diffuse, inflammatory form of lung injury in seriously ill patients characterized by poor oxygenation, pulmonary infiltrates, acute onset. Unadjusted hospitalization mortality was reported to be 35% among those w/ mild ARDS, 40% w/ moderate disease, 46% for patients w/ severe ARDS. AKB 9090 is Akebia’s ARDS drug. Filling an unmet need is defined as providing therapy where none exists or which may be potentially better than available therapy. Drug that receives Fast Track is eligible for accelerated approval/priority review. August of 2022, CEO Butler said Vadadustat was in trials for Covid-19/ARDS which was an “unmet medical need.” Butler was signaling intention to go after Fast Track status.
https://stocktwits.com/buythehornz127/message/559186953
👍️0
eyeownu eyeownu 9 months ago
John P. Butler, President and Chief Executive Officer of Akebia Therapeutics, Inc. (the “Company”), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the “Presentation”) at the 42 Annual J.P. Morgan
Healthcare Conference on January 11, 2024 at 11:15 a.m. PST, which includes preliminary unaudited net product revenue for Auryxia® cumulative and for the fiscal year ended December 31, 2023. Spokespersons of the Company also plan
to present the information in the Presentation at various meetings beginning on January 8, 2024, including investor and analyst meetings that coincide with the J.P. Morgan Healthcare Conference

https://ir.akebia.com/static-files/0be66d7f-9988-43fa-bcab-e587260e1dc0
👍️0
eyeownu eyeownu 9 months ago
easy money https://schrts.co/JdqbEsCN wait till the real news drops!
👍️0
eyeownu eyeownu 9 months ago
$AKBA shabba https://schrts.co/bYSHjBzF
👍️0
eyeownu eyeownu 9 months ago
this is looking good. if the RSI ever resets i'm going all in!
👍️0
eyeownu eyeownu 10 months ago
end of year. double top forming or is it slow and steady?
👍️0
glenn1919 glenn1919 1 year ago
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
AKBA full out weekly trend in place
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
AKBA MONSTER BREAK OUT
👍️0
glenn1919 glenn1919 1 year ago
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0

Your Recent History

NASDAQ
AKBA
Akebia Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved